Alimentary Pharmacology & Therapeutics

The management of severe Crohn's disease
pp. 563-573(11)
Authors: Parkes, M.; Jewell, D. P.

Current endoscopic therapeutic options in the management of variceal bleeding
pp. 575-594(20)
Authors: Helmy, A.; Hayes, P. C.

Erythromycin as a prokinetic agent in infants and children
pp. 595-603(9)
Authors: Curry, J. I.; Lander, T. D.; Stringer, M. D.

Colon cleansing preparation for gastrointestinal procedures
pp. 605-611(7)
Authors: Toledo, T. K.; Dipalma, J. A.

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole
pp. 613-624(12)
Authors: Janssen, M. J. R.; Van Oijen, A. H. A. M.; Verbeek, A. L. M.; Jansen, J. B. M. J.; De Boer, W. A.

Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine
pp. 625-630(6)
Authors: Hawkes, N. D.; Richardson, C.; Evans, B. K.; Rhodes, J.; Lewis, S. J.; Thomas, G. A. O.

Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis
pp. 631-638(8)
Authors: Arguedas, M. R.; Heudebert, G. R.; Wilcox, C. M.

Enhanced mucosal fibrinolytic activity in gastroduodenal ulcer haemorrhage and the beneficial effect of acid suppression
pp. 639-646(8)
Authors: Vreeburg, E. M.; Levi, M.; Rauws, E. A. J.; Deventer, S. J. H. V.; Snel, P.; Bartelsman, J. W. F. M.; Ten Cate, J. W.; Tytgat, G. N. J.

Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg
pp. 647-652(6)
Authors: Katz, P. O.; Xue, S.; Castell, D. O.

Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects
pp. 653-663(11)
Authors: Coulie, B.; Camilleri, M.; Bharucha, A. E.; Sandborn, W. J.; Burton, D.

In-vitro cyclosporin sensitivity of proliferating lymphocytes is predictive of in-vivo therapeutic response in ulcerative colitis
pp. 665-668(4)
Authors: McCormack, G.; O'Donoghue, D.; Baird, A.

A randomized controlled crossover study comparing synthetic porcine and human secretins with biologically derived porcine secretin to diagnose Zollinger-Ellison Syndrome
pp. 669-676(8)
Authors: Metz, D. C.; Buchanan, M.; Purich, E.; Fein, S.

Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C
pp. 677-687(11)
Authors: Pohle, T.; Brzozowski, T.; Becker, J. C.; Van Der Voort, I. R.; Markmann, A.; Konturek, S. J.; Moniczewski, A.; Domschke, W.; Konturek, J. W.

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis
pp. 689-698(10)
Authors: Papatheodoridis, G. V.; Papadimitropoulos, V. C.; Hadziyannis, S. J.

Rapid detection of anti-Helicobacter pylori IgG in urine using immunochromatography
pp. 699-702(4)
Authors: Graham, D. Y.; Reddy, S.

Evaluation of five commercial serological tests for the detection of Helicobacter pylori infection in Chinese
pp. 703-706(4)
Authors: Szeto, M. L.; Lee, C. K.; Yee, Y. K.; Li, K. F.; Lee, W. K.; Lee, C. C.; Que, T. L.; Wong, B. C. Y.

Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy
pp. 707-713(7)
Authors: Tankovic, J.; Lamarque, D.; Lascols, C.; Soussy, C. J.; Delchier, J. C.

Polaprezinc attenuates the Helicobacter pylori-induced gastric mucosal leucocyte activation in Mongolian gerbils—a study using intravital videomicroscopy
pp. 715-725(11)
Authors: Suzuki, H.; Mori, M.; Seto, K.; Miyazawa, M.; Kai, A.; Suematsu, M.; Yoneta, T.; Miura, S.; Ishii, H.

H. pylori-gastrin link in malt lymphoma
pp. 727-728(2)
Author: Beales, I. L. P.

Reply—Helicobacter pylori-gastrin link in malt-lymphoma
pp. 728-729(2)
Author: Konturek, Stanislaw J.

The safety of proton pump inhibitors
pp. 729-730(2)
Author: Waldum, Helge L.